GPT and metabolic dysfunction-associated steatohepatitis: Unlike the predicted non-NASH patients, these predicted NASH patients have mean AST and ALT levels above normal range (41.21 ± 144.28 U/L and 42.44 ± 99.86 U/L), and 66% (585,272/883,867) had T2DM in contrast to 53% (1,532,744/2,886,653) in the overall undiagnosed population.